Diffuse large B-cell lymphoma: 10 years' real-world clinical experience with rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisolone.

about

Diffuse large B-cell lymphoma: 10 years' real-world clinical experience with rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisolone.

Item

http://www.wikidata.org/entity/Q50319166

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Diffuse large B-cell lymphoma: ...... vincristine and prednisolone.

@en

Diffuse large B-cell lymphoma: ...... vincristine and prednisolone.

@nl

type

Item

label

Diffuse large B-cell lymphoma: ...... vincristine and prednisolone.

@en

Diffuse large B-cell lymphoma: ...... vincristine and prednisolone.

@nl

prefLabel

Diffuse large B-cell lymphoma: ...... vincristine and prednisolone.

@en

Diffuse large B-cell lymphoma: ...... vincristine and prednisolone.

@nl

P1476

Diffuse large B-cell lymphoma: ...... vincristine and prednisolone.

@en

P2093

Barbara Jezeršek Novaković

http://www.w3.org/2001/XMLSchema#string

Jana Pahole Goličnik

http://www.w3.org/2001/XMLSchema#string

Lučka Boltežar

http://www.w3.org/2001/XMLSchema#string

Matej Horvat

http://www.w3.org/2001/XMLSchema#string

Srdjan Novaković

http://www.w3.org/2001/XMLSchema#string

Tanja Južnič Šetina

http://www.w3.org/2001/XMLSchema#string

Vesna Zadnik

http://www.w3.org/2001/XMLSchema#string

P2860

Evolution of frontline treatment of diffuse large B-cell lymphoma: a brief review and recent update

A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project

The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP

Validation of clinical prognostic indices for diffuse large B-cell lymphoma in the National Cancer Data Base.

Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: an open-label, randomised, phase 3 trial (DSHNHL 2002-1).

Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte.

CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group.

Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification

Survival impact of rituximab combined with ACVBP and upfront consolidation autotransplantation in high-risk diffuse large B-cell lymphoma for GELA.

Continued Risk of Relapse Independent of Treatment Modality in Limited-Stage Diffuse Large B-Cell Lymphoma: Final and Long-Term Analysis of Southwest Oncology Group Study S8736.

P304

3602-3609

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3892/OL.2018.7774

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-01-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29467881

http://www.w3.org/2001/XMLSchema#string

P932

5796369

http://www.w3.org/2001/XMLSchema#string